Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Founder of the awards Sir Leonard Blavatnik said "We are incredibly proud to elevate these select scientists to an international stage that will enable them to be recognised globally, prepare them to become world-class leaders in their scientific fields, and propel the wheel of innovation and societal progress."

Horizontal portrait of Eleanor Stride

Professor Eleanor Stride, Statutory Professor of Biomaterials in the Departments of Engineering Science and the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), has been announced as a Finalist in the 2020 Blavatnik Awards for Young Scientists in the United Kingdom by the Blavatnik Family Foundation and New York Academy of Sciences. The awards are the largest unrestricted cash prizes available to scientists under the age of 42.

A jury of leading scientists from across the UK selected one Laureate and two Finalists in each of three categories – Life Sciences, Chemistry and Physical Sciences & Engineering. The awards are given to scientists recognised for their innovative discoveries and advances in these areas which are already changing science and our understanding of the world, despite being still in the early stages of their careers.

Professor Stride is using microbubble technology to design better ways of delivering powerful drugs directly to where they are needed without damaging other parts of the body. She says, "My research looks at several different challenges, all related to improving the delivery of drugs to specific sites in the body. The first is trying to understand the barriers that exist in tissue that prevent drugs from reaching their target. Second, is studying how those can be overcome, for example by generating localised flow or breaking down physical barriers. Third is designing drug delivery vehicles in the form or micro and nanoparticles that can be activated from outside the body to get the drugs across those tissue barriers. To do this we have had to develop not only the delivery vehicles but also new techniques for studying them and their interactions with tissue – for example using new types of fluorescence microscopy and high speed imaging".

The Blavatnik Award winners are selected by a distinguished jury of leading senior scientists and engineers from throughout the UK. The New York Academy of Sciences' Chief Scientific Officer, Scientific Programs and Awards, Dr. Brooke Grindlinger, explains what captured the jury's attention about Professor Stride's research. "As a leader in the field of microbubble bioengineering, Professor Eleanor Stride is pushing the boundary of what we think is possible in clinical translational research. From the development of microbubbles as drug delivery vessels and their directed use as therapy for disease, to the creation of startup companies and public engagement, Professor Stride is a bold, young innovator improving lives and inspiring minds."

Professor Stride says of her award, "It is a huge honour to receive the Blavatnik award both for me personally but much more importantly for our research group as a whole. It is very valuable, particularly for translational research, to have this sort of international recognition; and for an engineering team to receive a Life Sciences award is really exciting".

Professor Stride, along with the other 2020 Laureates and Finalists, will be honoured at a black-tie gala dinner and ceremony at Banqueting House in London on 4th March 2020. The following day, the honourees will present their research with a series of short, interactive lectures at a public symposium, "Game Changers: 9 Young Scientists Transforming Our World". The event is free and open to the public. 

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.